Group 1 - The core viewpoint of the articles highlights the strong momentum of China's innovative pharmaceuticals in the global market, with significant growth in business development (BD) transactions and supportive policy measures [1][2]. - The Hang Seng Innovative Drug ETF (520500) has shown high trading activity, with an average daily turnover of 624 million yuan since 2026, and a fund size of 2.102 billion yuan, indicating strong investor interest [1]. - In 2025, China completed 157 BD transactions for innovative drugs, totaling 135.655 billion USD, with 7 billion USD in upfront payments, marking a historical high [1]. Group 2 - The report indicates that in 2025, China accounted for 49% of the global BD transaction total, surpassing the United States for the first time, with eight out of the top ten global license-out transactions originating from China [1][2]. - The policy environment is supportive, as the Ministry of Commerce and other departments have issued guidelines to enhance the drug retail industry, encouraging innovative drugs to enter retail pharmacy sales channels [1]. - Looking ahead to 2026, the trend of Chinese innovative drugs going global is expected to continue, with a focus on clinical progress and data validation of pipelines that have already gone abroad [2].
中国创新药BD出海创历史纪录，恒生创新药ETF(520500)开年以来日均成交额超6亿
Xin Lang Cai Jing·2026-01-26 03:34